



## Verastem to Present at the Oppenheimer 27th Annual Healthcare Conference

March 15, 2017

BOSTON--(BUSINESS WIRE)--Mar. 15, 2017-- Verastem, Inc. (NASDAQ:VSTM), focused on discovering and developing drugs to treat cancer, today announced that the company will present at the Oppenheimer 27<sup>th</sup> Annual Healthcare Conference on Tuesday, March 21<sup>st</sup> at 2:10 p.m. ET at the Westin Grand Central in New York City.

A live audio webcast of the presentation will be available on the company's website at [www.verastem.com](http://www.verastem.com). An archived presentation will be available for 90 days.

### About Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is a biopharmaceutical company focused on discovering and developing drugs to improve outcomes for patients with cancer. Verastem is currently developing duvelisib, a dual inhibitor of phosphoinositide-3-kinase (PI3K)-delta and PI3K-gamma, which has successfully met its primary endpoint in a Phase 2 study and is currently being evaluated in a Phase 3 clinical trial in patients with chronic lymphocytic leukemia (CLL). Other clinical product candidates include focal adhesion kinase (FAK) inhibitors defactinib and VS-4718, and dual PI3K/mTOR inhibitor VS-5584. Defactinib is currently being evaluated in three separate clinical collaborations in combination with immunotherapeutic agents for the treatment of several different cancer types, including pancreatic, ovarian and non-small cell lung cancer, and mesothelioma. Verastem's product candidates seek to treat cancer by modulating the local tumor microenvironment, enhancing anti-tumor immunity and reducing cancer stem cells. For more information, please visit [www.verastem.com](http://www.verastem.com).

View source version on businesswire.com: <http://www.businesswire.com/news/home/20170315006410/en/>

Source: Verastem, Inc.

### Verastem, Inc.

Brian Sullivan, 781-292-4214  
Director, Corporate Development  
[bsullivan@verastem.com](mailto:bsullivan@verastem.com)